Nampt: a new therapeutic target for modulating NAD + levels in metabolic, cardiovascular, and neurodegenerative diseases
Canadian Journal of Physiology and Pharmacology · 2025
DOI: 10.1139/cjpp-2024-0400 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Canadian Journal of Physiology and Pharmacology, 2025. Verfasst von Ravikumar Manickam und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, Taneja College of Pharmacy, University of South Florida, Tampa, FL 33612, USA. Hauptthemen laut MEDLINE: Nicotinamide Phosphoribosyltransferase, NAD, Neurodegenerative Diseases, Cardiovascular Diseases. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 235 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Saunders Endowment for Geriatric Pharmacotherapy, National Institute of Diabetes and Digestive and Kidney Diseases, Florida High Tech Corridor's Undergraduate Research Initiative.
Abstract (Originalsprache)
NAD + is an important cofactor involved in regulating many biochemical processes in cells. An imbalance in NAD + /NADH ratio is linked to many diseases. NAD + is depleted in diabetes, cardiovascular and neurodegenerative diseases, and in aging, and is increased in tumor cells. NAD + is generated in cells via the de novo, Preiss–Handler, and salvage pathways. Most of the cellular NAD + is generated through Nampt activation, a key rate-limiting enzyme that is involved in the salvage pathway. Restoration of NAD + /NADH balance offers therapeutic advantages for improving tissue homeostasis and function. NAD + is known to benefit and restore the body’s physiological mechanisms, including DNA replication, chromatin and epigenetic modifications, and gene expression. Recent studies elucidate the role of NAD + in cells utilizing transgenic mouse models. Translational new therapeutics are positioned to utilize the NAD + restoration strategies for overcoming the drawbacks that exist in the pharmacological toolkit. The present review highlights the significance of Nampt-NAD + axis as a major player in energy metabolism and provides an overview with insights into future strategies, providing pharmacological advantages to address current and future medical needs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, Taneja College of Pharmacy, University of South Florida, Tampa, FL 33612, USA.
- Department of Chemistry, College of Arts and Sciences, University of South Florida, Tampa, FL 33620, USA.
ORCID-Profile: Wanling Xuan, Srinivas M Tipparaju
Förderung
- Saunders Endowment for Geriatric Pharmacotherapy
- National Institute of Diabetes and Digestive and Kidney Diseases
- Florida High Tech Corridor's Undergraduate Research Initiative
Zitieren
APA
Manickam, R., Santhana, S., Xuan, W., Bisht, K., & Tipparaju, S. (2025). Nampt: a new therapeutic target for modulating NAD + levels in metabolic, cardiovascular, and neurodegenerative diseases. Canadian Journal of Physiology and Pharmacology. https://doi.org/10.1139/cjpp-2024-0400
Vancouver
Manickam R, Santhana S, Xuan W, Bisht K, Tipparaju S. Nampt: a new therapeutic target for modulating NAD + levels in metabolic, cardiovascular, and neurodegenerative diseases. Canadian Journal of Physiology and Pharmacology. 2025. doi:10.1139/cjpp-2024-0400
BibTeX
@article{Manickam2025,
author = {Manickam, Ravikumar and Santhana, Sandhya and Xuan, Wanling and Bisht, Kirpal S and Tipparaju, Srinivas M},
title = {Nampt: a new therapeutic target for modulating NAD + levels in metabolic, cardiovascular, and neurodegenerative diseases},
journal = {Canadian Journal of Physiology and Pharmacology},
year = {2025},
doi = {10.1139/cjpp-2024-0400}
}
EUVIMED